{"title":"重症肌无力与多发性硬化症并存:病例报告","authors":"G. Rynkevič, R. Kizlaitienė","doi":"10.29014/ns.2023.27.13","DOIUrl":null,"url":null,"abstract":"Myasthenia gravis (MG) and multiple sclerosis (MS) are thought to have a common autoimmune mechanism as the number of reported co-occurrences of both diseases is increasing. The involvement of both T cells and B cells in the pathogenesis of these two diseases is suspected. As the symptoms and clinical course of MS and MG can be similar in some cases, this makes it difficult to consider the possibility of the coexistence of these disorders. However, laboratory and imagining findings are helpful in distinguishing both diseases and differentiating them from other neurological conditions. Additionally, there can be obstacles in effective treatment selection for patients with MS and MG coexistence. This article presents a clinical case of a woman with previously diagnosed MG who was admitted to hospital 12 years later with new-onset symptoms and was additionally diagnosed with relapsing-remitting multiple sclerosis (RRMS). Remission of MG was achieved with medications and thymectomy, but treatment of MS had its challenges, as first-line immunomodulating drugs interferon beta-1a and dimethyl fumarate were not effective, and second line treatment with monoclonal antibody medication rituximab and ocrelizumab showed efficacy for both diseases, MG and MS. The presented case highlights the importance of considering a manifestation of another disease when treating an already diagnosed disorder. It also emphasizes the importance of further research into the relationship between MG and MS. \n ","PeriodicalId":479531,"journal":{"name":"Neurologijos seminarai","volume":"118 49","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Co-occurrence of Myasthenia Gravis and Multiple Sclerosis: A Case Report\",\"authors\":\"G. Rynkevič, R. Kizlaitienė\",\"doi\":\"10.29014/ns.2023.27.13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Myasthenia gravis (MG) and multiple sclerosis (MS) are thought to have a common autoimmune mechanism as the number of reported co-occurrences of both diseases is increasing. The involvement of both T cells and B cells in the pathogenesis of these two diseases is suspected. As the symptoms and clinical course of MS and MG can be similar in some cases, this makes it difficult to consider the possibility of the coexistence of these disorders. However, laboratory and imagining findings are helpful in distinguishing both diseases and differentiating them from other neurological conditions. Additionally, there can be obstacles in effective treatment selection for patients with MS and MG coexistence. This article presents a clinical case of a woman with previously diagnosed MG who was admitted to hospital 12 years later with new-onset symptoms and was additionally diagnosed with relapsing-remitting multiple sclerosis (RRMS). Remission of MG was achieved with medications and thymectomy, but treatment of MS had its challenges, as first-line immunomodulating drugs interferon beta-1a and dimethyl fumarate were not effective, and second line treatment with monoclonal antibody medication rituximab and ocrelizumab showed efficacy for both diseases, MG and MS. The presented case highlights the importance of considering a manifestation of another disease when treating an already diagnosed disorder. It also emphasizes the importance of further research into the relationship between MG and MS. \\n \",\"PeriodicalId\":479531,\"journal\":{\"name\":\"Neurologijos seminarai\",\"volume\":\"118 49\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurologijos seminarai\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.29014/ns.2023.27.13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologijos seminarai","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.29014/ns.2023.27.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
重症肌无力(MG)和多发性硬化症(MS)被认为具有共同的自身免疫机制,因为这两种疾病的并发报道越来越多。人们怀疑 T 细胞和 B 细胞都参与了这两种疾病的发病机制。在某些病例中,多发性硬化症和间质性硬化症的症状和临床过程可能相似,因此很难考虑这两种疾病同时存在的可能性。不过,实验室和影像学检查结果有助于区分这两种疾病,并将它们与其他神经系统疾病区分开来。此外,多发性硬化症和间质性硬化症并存的患者在选择有效治疗方法时可能会遇到障碍。本文介绍了一例临床病例:一名女性患者曾被诊断为多发性硬化症,12 年后因新发症状入院,同时被诊断为复发缓解型多发性硬化症(RRMS)。由于一线免疫调节药物干扰素 beta-1a 和富马酸二甲酯疗效不佳,单克隆抗体药物利妥昔单抗和奥克立珠单抗的二线治疗对 MG 和 MS 两种疾病都有疗效。本病例强调了在治疗已确诊的疾病时考虑另一种疾病表现的重要性。它还强调了进一步研究 MG 和多发性硬化症之间关系的重要性。
Co-occurrence of Myasthenia Gravis and Multiple Sclerosis: A Case Report
Myasthenia gravis (MG) and multiple sclerosis (MS) are thought to have a common autoimmune mechanism as the number of reported co-occurrences of both diseases is increasing. The involvement of both T cells and B cells in the pathogenesis of these two diseases is suspected. As the symptoms and clinical course of MS and MG can be similar in some cases, this makes it difficult to consider the possibility of the coexistence of these disorders. However, laboratory and imagining findings are helpful in distinguishing both diseases and differentiating them from other neurological conditions. Additionally, there can be obstacles in effective treatment selection for patients with MS and MG coexistence. This article presents a clinical case of a woman with previously diagnosed MG who was admitted to hospital 12 years later with new-onset symptoms and was additionally diagnosed with relapsing-remitting multiple sclerosis (RRMS). Remission of MG was achieved with medications and thymectomy, but treatment of MS had its challenges, as first-line immunomodulating drugs interferon beta-1a and dimethyl fumarate were not effective, and second line treatment with monoclonal antibody medication rituximab and ocrelizumab showed efficacy for both diseases, MG and MS. The presented case highlights the importance of considering a manifestation of another disease when treating an already diagnosed disorder. It also emphasizes the importance of further research into the relationship between MG and MS.